Phage display antibody library and monoclonal antibodies aiming at novel coronavirus SARS-CoV-2 and obtained by panning based on same

Abstract

The invention discloses a phage display antibody library and five strains of screened antibodies capable of being combined with S protein of novel coronavirus SARS-CoV-2. Mutation is introduced into an ultra-variable region of an antibody variable region based on synthetic biology and a phage display technology, and a gene is transferred into escherichia coli, so that a synthetic antibody librarycontaining 108 kinds of antibodies is constructed; the phage display antibody library provided by the invention can perform screening to obtain the antibody with the specificity and the detection function, so that powerful resources of biological research and medical diagnosis are expanded; and the five strains of antibodies capable of being combined with the S protein of the novel coronavirus arefurther screened out and can be used for detecting the virus, part of the antibodies can block combination of the virus and cells, and the antibodies have the capacity of neutralizing novel coronavirus infectivity, can be used for preparing a novel coronavirus detection product, preparing a drug for inhibiting the novel coronavirus and preparing a pharmaceutical preparation for preventing or treating diseases caused by the novel coronavirus, and have a wide application prospect.

Description

technical field [0001] The present invention relates to the technical fields of biomedicine and molecular biology, specifically a phage display antibody library and a monoclonal antibody against the new coronavirus SARS-CoV-2 obtained by panning the phage display antibody library. Background technique [0002] Compared with the original coronavirus, SARS-CoV-2 is not only contagious in patients with severe symptoms, but also in patients with mild symptoms and even in the incubation period. There are many ways of transmission, and it can be transmitted by droplets and contact. It has brought great difficulties to prevention. [0003] Various countries have proposed a variety of treatment options for the treatment of new coronary pneumonia, mainly using the small molecule drug remdesivir, the combination of chloroquine and hydroxychloroquine, the combination of lopinavir and ritonavir, and the combination of lopinavir and ritonavir. Unfortunately, the three-drug combination o...

AI Technical Summary

Problems solved by technology

[0002] Compared with the original coronavirus, SARS-CoV-2 is not only contagious in patients with severe symptoms, but also in patients with mild symptoms and even in the incubation period. There are many ways of transmission, and it can be transmitted by droplets and contact. It is very difficult to prevent

[0003] Various countries have proposed a variety of treatment options for the treatment of new coronary pneumonia, mainly using the small molecule drug remdesivir, the combination of chloroquine and hydroxychloroquine, the combination of lopinavir and ritonavir, and the combination of lopinavir and ritonavir. Unfortunately, the three-drug combination of navir and interferon has no obvious therapeutic effect and some have serious side effects

Images